OSLO, Norway, Feb. 16, 2022 /PRNewswire/ -- Navamedic ASA
(OSE: NAVA) today announces the launch of
SmectaGO® for sale through pharmacies in
Norway, Sweden, Finland and Denmark this spring. SmectaGO® is a
unique product developed to treat acute and chronic diarrhea in
adults and children above 8 years. The launch is part of a
long-term agreement with the well known French pharmaceutical
corporation Ipsen Consumer HealthCare wherein Navamedic has been
appointed the exclusive partner in the Nordics.
"Diarrhea and other gastro conditions are very common, but in
the Nordics, we know from research that only 20 percent of those
suffering from such conditions seek treatment. We can improve many
people's lives through driving awareness and knowledge of treatment
options. With our local insights and market access, Navamedic
intends to drive the development of this category in the Nordics,
and with SmectaGO®, we can offer a unique product to
Nordic consumers. SmectaGO® is already well
established on the European continent and has been a favourite for
a long time for the treatment of diarrhea. We are honored that
Ipsen Consumer HealthCare selected Navamedic as their Nordic
partner for this product range," says Kathrine Gamborg Andreassen, CEO of Navamedic
ASA.
"This cooperation embodies the purpose of our Consumer
HealthCare Division, which is to bring people across the world care
and comfort in their daily lives with healthcare solutions they can
trust. Indeed, it is a great opportunity to touch more patients
with an innovative and proven effective product against
diarrhea," says Djamel Oulali,
Senior Director Export in Ipsen Consumer HealthCare.
SmectaGo® is a ready-to-drink suspension for use
in the treatment of acute diarrhea in adults and children above 8
years of age. The main component of the product is diosmectite, a
natural clay that helps in the inhibition and treatment of diarrhea
and in relieving abdominal pain.
Diarrhea is a common disease that affects adults and children
from time to time, and some patients suffer from chronic
conditions. In Norway alone,
intestinal disorders accounts for up to 5 000 consultations
per week with general practicioners. SmectaGO® is a
product that can be bought in the pharmacies without any
prescription, and is different from any other product on the market
and uniquely characterized by its "stop and treat" mode of
action:
- Ready to drink for a fast intake on the go
- Removes the toxins and germs
- Helps to repair intestinal damage
- Relieves abdominal pain
The agreement with Ipsen Consumer HealthCare will strengthen
Navamedic's position in the gastroenterology category, which
represents a significant growth potential in the Consumer Health
segment where patients can find approved treatment options without
prescriptions in the pharmacies. As part of the agreement,
Navamedic will also take over the distribution and sales in
Sweden of Forlax®, a prescription
drug for the treatment of constipation in adults and children aged
8 years and above.
"Navamedic has a target of 20 percent annual organic growth and
the mid-term ambition of building a NOK 500
million company, as we continue to accelerate growth through
launch of new products and push for growth in our existing
portfolio. The launch of SmectaGO® is a perfect example on how we
like to develop categories and drive growth," says Kathrine Gamborg Andreassen, CEO of Navamedic
ASA.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO,
Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
Navamedic ASA is a Nordic pharma company and reliable
provider of high-quality products, delivered to hospitals and
through pharmacies, meeting the specific needs of patients and
consumers by leveraging its highly scalable market access platform,
leading category competence and local knowledge. Navamedic is
present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com
This information is subject to the disclosure requirements
pursuant to section 5 -12 of the Norwegian Securities Trading
Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-asa-launches-smectago----an-innovative-on-the-go-product-for-treatment-of-diarrhea,c3508224